NEW DELHI: Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said clinical trials of Covid-19 vaccine Covovax have begun in India and the company hopes to launch it by September this year.
In August 2020, American vaccine company Novavax, Inc had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its Covid-19 vaccine candidate, in low and middle-income countries and India.
“Covovax trials finally begin in India; the vaccine is made through a partnership with @Novavax and @SerumInstIndia. It has been tested against African and UK variants of #Covid19 and has an overall efficacy of 89%. Hope to launch by September 2021!,” Poonawalla said in a tweet.
Covovax trials begin in India, hope to launch it by Sept 2021: Adar Poonawalla – Times of India
Published in News
More from NewsMore posts in News »
- Citigroup to sell off consumer business in India – The Indian Express
- India to process Covid vaccine import license in 3 working days post approval – Hindustan Times
- India to Receive Sputnik V Vaccine Doses This Month – Russian Media – News18
- Amazon’s Future CEO Andy Jassy Doubles Down On India Despite Challenges – NDTV
- Citibank Exit: Looking for Buyers for Business in India, No Impact on Existing Customers, Says Official – news18.com
